Table 1.
Demographic and Clinical Characteristics of the Study Population in Group 1
| CD | UC | DC | HC | |
|---|---|---|---|---|
| Number, n | 145 | 91 | 50 | 32 |
| Female, n (%) | 58 (40) | 38 (41.8) | 17 (34) | 17 (53.1) |
| Age, y | 32 (25–44) | 39 (28–51) | 31 (27.8–42.5) | 31 (26–47.8) |
| Disease duration, y | 1 (0–5) | 1.5 (0.4–6) | ||
| BMI, kg/m2 | 19.7 (18.1–21.3) | 20.8 (19.2–22.6) | 21.5 (19.5–24.6) | 21.9 (19.6–25.6) |
| Family history, n (%) | 2 (1.4) | 1 (1.1) | ||
| CD behavior, n (%) | ||||
| Nonpenetrating, not stricturing (B1) | 54 (37.2) | |||
| Stricturing (B2) | 64 (44.1) | |||
| Penetrating (B3) | 27 (18.6) | |||
| CD location, n (%) | ||||
| Ileal (L1) | 51 (35.2) | |||
| Colonic (L2) | 13 (9) | |||
| Ileocolonic (L3) | 81 (55.9) | |||
| UC location, n (%) | ||||
| Proctitis (E1) | 20 (22) | |||
| Left-sided (E2) | 25 (27.5) | |||
| Pancolitis (E3) | 46 (50.5) | |||
| Clinical remission, n (%) | 85 (58.6) | 42 (46.2) | ||
| Perianal lesions, n (%) | 83 (57.2) | 3 (3.3) | ||
| Extraintestinal manifestation, n (%) | 29 (20) | 8 (8.8) | ||
| Previous perianal surgery, n (%) | 47 (32.4) | 2 (2.2) | ||
| Previous bowel surgery, n (%) | 45 (31) | 1 (1.1) | ||
| Medication, n (%) | ||||
| 5-aminosalicylic acid | 83 (57.2) | 80 (87.9) | ||
| Corticosteroids | 65 (44.8) | 45 (49.5) | ||
| Azathioprine/6-mercaptopurine | 60 (41.4) | 17 (18.7) | ||
| Methotrexate | 20 (13.8) | 7 (7.7) | ||
| Thalidomide | 14 (9.7) | 8 (8.8) | ||
| Anti-TNF | 85 (58.6) | 24 (26.4) |